NeuroMetrix (NASDAQ:NURO) Coverage Initiated by Analysts at StockNews.com

Investment analysts at StockNews.com began coverage on shares of NeuroMetrix (NASDAQ:NURO) in a note issued to investors on Monday. The firm set a “sell” rating on the medical device company’s stock.

NeuroMetrix Stock Up 1.5 %

NASDAQ:NURO opened at $4.40 on Monday. NeuroMetrix has a 52 week low of $2.66 and a 52 week high of $4.73. The company has a fifty day moving average of $4.41 and a 200 day moving average of $4.19. The firm has a market capitalization of $9.07 million, a P/E ratio of -0.96 and a beta of 1.82.

Hedge Funds Weigh In On NeuroMetrix

A hedge fund recently bought a new stake in NeuroMetrix stock. Renaissance Technologies LLC purchased a new stake in shares of NeuroMetrix, Inc. (NASDAQ:NURO) during the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm purchased 11,560 shares of the medical device company’s stock, valued at approximately $46,000. Renaissance Technologies LLC owned about 0.57% of NeuroMetrix as of its most recent SEC filing. 19.40% of the stock is owned by institutional investors.

About NeuroMetrix

NeuroMetrix, Inc, a commercial stage neurotechnology company, engages in designing, building, and marketing medical devices that stimulate and analyze nerve response for diagnostic and therapeutic purposes in the United States, Europe, Japan, and China. Its marketed products include DPNCheck, a nerve conduction test that is used to evaluate peripheral neuropathies, such as diabetic peripheral neuropathy; Quell, a wearable device for symptomatic relief and management of chronic pain; and ADVANCE system offers services to device and provide disposable electrodes to a customer base of hand surgeons and manufacturers for industrial health use.